CASI Pharmaceuticals, Inc. (CASI) Given $3.50 Consensus Price Target by Brokerages
Shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) have earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Brokers have set a 1-year consensus target price of $3.50 for the company and are expecting that the company will post ($0.04) EPS for the current quarter, according to Zacks. Zacks has also given CASI Pharmaceuticals an industry rank of 102 out of 265 based on the ratings given to its competitors.
CASI has been the topic of several analyst reports. Maxim Group set a $4.00 target price on CASI Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, August 14th. HC Wainwright reiterated a “buy” rating and set a $2.00 target price on shares of CASI Pharmaceuticals in a research report on Friday, September 8th. Finally, ValuEngine upgraded CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 15th.
CASI Pharmaceuticals (CASI) traded up $0.61 during mid-day trading on Thursday, hitting $3.63. The stock had a trading volume of 1,254,300 shares, compared to its average volume of 239,797. CASI Pharmaceuticals has a 52-week low of $0.91 and a 52-week high of $4.84.
CASI Pharmaceuticals (NASDAQ:CASI) last released its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.01. research analysts predict that CASI Pharmaceuticals will post -0.15 earnings per share for the current year.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.